Evidence map›Paper›PMID 36382390›Full record

ArticleEuropean heart journal2023

Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study.

Lotte M de Boer, Barbara A Hutten, Aeilko H Zwinderman, Albert Wiegman

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.American heart journal plus : cardiology research and practice · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Lipoprotein (a) and cerebrovascular disease.The Journal of international medical research · 2024
    Review
  12. Article
  13. Article
  14. Advances in laboratory medicine · 2023
    Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lotte M de BoerEpidemiology and Data Science, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, TheNetherlands.ORCID 0000-0002-1208-354X
Barbara A HuttenEpidemiology and Data Science, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, TheNetherlands.ORCID 0000-0002-9243-0037
Aeilko H ZwindermanEpidemiology and Data Science, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, TheNetherlands.ORCID 0000-0003-0361-3139
Albert WiegmanPediatrics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, TheNetherlands.ORCID 0000-0001-6223-5671
Amsterdam University Medical Centers · NLGGD Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsFamilial hypercholesterolaemia (FH) predisposes children to the early initiation of atherosclerosis and is preferably diagnosed by DNA analysis. Yet, in many children with a clinical presentation of FH, no mutation is found. Adult data show that high levels of lipoprotein(a) [Lp(a)] may underlie a clinical presentation of FH, as the cholesterol content of Lp(a) is included in conventional LDL cholesterol measurements. As this is limited to adult data, Lp(a) levels in children with and without (clinical) FH were evaluated. METHODS AND

resultsChildren were eligible if they visited the paediatric lipid clinic (1989-2020) and if Lp(a) measurement and DNA analysis were performed. In total, 2721 children (mean age: 10.3 years) were included and divided into four groups: 1931 children with definite FH (mutation detected), 290 unaffected siblings/normolipidaemic controls (mutation excluded), 108 children with probable FH (clinical presentation, mutation not detected), and 392 children with probable non-FH (no clinical presentation, mutation not excluded). In children with probable FH, 32% were found to have high Lp(a) [geometric mean (95% confidence interval) of 15.9 (12.3-20.6) mg/dL] compared with 10 and 10% [geometric means (95% confidence interval) of 11.5 (10.9-12.1) mg/dL and 9.8 (8.4-11.3) mg/dL] in children with definite FH (P = 0.017) and unaffected siblings (P = 0.002), respectively.

conclusionLp(a) was significantly higher and more frequently elevated in children with probable FH compared with children with definite FH and unaffected siblings, suggesting that high Lp(a) may underlie the clinical presentation of FH when no FH-causing mutation is found. Performing both DNA analysis and measuring Lp(a) in all children suspected of FH is recommended to assess possible LDL cholesterol overestimation related to increased Lp(a).

Indexed as

Hyperlipoproteinemia Type IILipoprotein(a)ChildCholesterol, LDLCross-Sectional StudiesDNAHumansMutationCholesterol, LDLDNALipoprotein(a)ChildrenDNA analysisFamilial hypercholesterolaemiaFHLipoprotein(a)Lp(a)

Identifiers

PMID36382390
PMCPMC10119030
OpenAlexW4309164330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.